About
Drug Development for Fibrotic Lung Diseases
Noxon develops a novel drug for oral treatment of fibrotic lung diseases. The developed drug, 3-cabamoyl-proxyl, is a stable organic radical belonging to the nitroxides group.
Its product, 3-CP, which has a unique antioxidant property, has been shown to reduce airway inflammation, airway hyper-responsiveness, and other inflammatory mediators of the lung tissues, as seen in animal models of allergic asthma.
Identity
| Name | Noxon |
|---|---|
| Slug | noxon |
| Type / kind | startup |
| Source _id | y7H1UjnacZ3KX61AazpM4spmIy9ZfWfcFLJDZDgeRBvkAZ93RbY489 |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ city | Nazareth |
| HQ address | Wadi el-Haj St 13, Nazareth, Israel |
Web & social
| Website | https://ngt-healthcare2.com/noxon/ |
|---|
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B2C
Tags
pharmaceuticalsdrug-discoveryhealthcareoral-drugs
Funding
| Total raised | — |
|---|---|
| Current stage | Pre-Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}